China's Sinopharm 30 Times Oversubscribed At Start Of Hong Kong IPO
This article was originally published in PharmAsia News
Executive Summary
The day China's Sinopharm Group launched an initial public offering on the Hong Kong stock exchange, it already was nearly 30 times oversubscribed, with some major global investors among those making purchases